ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at StockNews.com

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also issued reports on the stock. Citigroup upped their target price on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. Finally, Chardan Capital restated a “buy” rating and issued a $2.50 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, ProQR Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $3.38.

ProQR Therapeutics Trading Up 0.6 %

Shares of ProQR Therapeutics stock opened at $1.66 on Friday. The company has a fifty day moving average price of $1.88 and a 200 day moving average price of $2.04. ProQR Therapeutics has a twelve month low of $1.11 and a twelve month high of $3.29. The stock has a market cap of $135.06 million, a price-to-earnings ratio of -4.49 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. The firm had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.31 million. Analysts forecast that ProQR Therapeutics will post -0.37 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC boosted its holdings in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after acquiring an additional 10,958 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth approximately $26,000. BNP Paribas Financial Markets lifted its position in ProQR Therapeutics by 120.1% in the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 19,100 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth approximately $56,000. Finally, RFG Advisory LLC acquired a new position in shares of ProQR Therapeutics during the 1st quarter worth $73,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).